2524-67-6

Usage

Uses

Used in Pharmaceutical Industry:
4-Morpholinoaniline is used as an intermediate in the synthesis of central nervous system (CNS) active agents. It plays a crucial role in the development of medications targeting neurological disorders and conditions, contributing to the advancement of treatments and therapies in this field.
Used in Photography Industry:
In the realm of photography, 4-Morpholinoaniline serves as one of the primary aromatic amines utilized in the color developing process. Its chemical properties facilitate the formation of color images in photographic films, making it an essential component in the production of high-quality photographs.

InChI:InChI=1/C10H14N2O/c11-9-1-3-10(4-2-9)12-5-7-13-8-6-12/h1-4H,5-8,11H2

Upstream product

• 5382-54-7 4-(4-nitroso-phenyl)-morpholine 
• 10389-51-2 1-morpholino-4-nitrobenzene 
• 110-91-8 morpholine 
• 106-40-1 4-bromo-aniline 
• 92-53-5 4-Phenylmorpholine 
• 70291-67-7 N-(4-chlorophenyl)morpholine 
• 106-47-8 4-chloro-aniline 
• 30483-75-1 4-bromophenyl-morpholine 
• 589-87-7 1,4-bromoiodobenzene 
• 39910-98-0 4-morpholinoacetophenone 
• 115833-91-5 1-(4-(4-morpholinylphenyl))ethan-1-ol 
• 371-40-4 4-fluoroaniline 
• 106-39-8 bromochlorobenzene 
• 100-00-5 4-chlorobenzonitrile 

Downstream Products

• 16153-98-3 N-furfurylidene-4-morpholino-aniline 
• 4433-80-1 acetoacetic acid-(4-morpholino-anilide) 
• 7253-93-2 2-[(4-Morpholino-phenylimino)-methyl]-phenol 
• 301157-20-0 N-(4-morpholinophenylcarbamothioyl)benzamide 
• 130956-92-2 2-methyl-4-(4-morpholino-phenylimino)-cyclohexa-2,5-dienone 
• 95003-50-2 3-hydroxy-[2]naphthoic acid-(4-morpholino-anilide) 
• 103913-29-7 N-(4-morpholin-4-yl-phenyl)-acetamide 
• 95319-82-7 acridin-9-yl-(4-morpholin-4-yl-phenyl)-amine 
• 68944-95-6 4-morpholin-4-yl-N-(2-p-tolyl-indol-3-ylmethylene)-aniline 
• 27311-28-0 2-hydroxy-N-(4-morpholin-4-yl-phenyl)-2-phenyl-acetamide 
• 104686-86-4 (7-methyl-1⁽³⁾H-imidazo[4,5-f]quinolin-9-yl)-(4-morpholin-4-yl-phenyl)-amine 
• 86818-85-1 2-(4-Methoxy-phenyl)-3-(4-morpholin-4-yl-phenyl)-5-[1-phenyl-meth-(Z)-ylidene]-3,5-dihydro-imidazol-4-one 
• 86818-90-8 2-(4-Chloro-phenyl)-5-[1-(4-methoxy-phenyl)-meth-(Z)-ylidene]-3-(4-morpholin-4-yl-phenyl)-3,5-dihydro-imidazol-4-one 
• 86818-89-5 2-(4-Methoxy-phenyl)-5-[1-(4-methoxy-phenyl)-meth-(Z)-ylidene]-3-(4-morpholin-4-yl-phenyl)-3,5-dihydro-imidazol-4-one 

Relevant academic research and scientific papers

Method for preparing amine through catalytic reduction of nitro compound by cyclic (alkyl) (amino) carbene chromium complex

The cyclic (alkyl) (amino) carbene chromium complex is prepared from corresponding ligand salt, alkali and CrCl3 and used for catalyzing pinacol borane to reduce nitro compounds in an ether solvent under mild conditions to generate corresponding amine. The method for preparing amine has the advantages of cheap and accessible raw materials, mild reaction conditions, wide substrate application range, high selectivity and the like, and is simple to operate.

Synthesis method of linezolid intermediate

The invention provides a synthesis method of a linezolid intermediate 3-fluoro-4-(4-morpholinyl)aniline. The linezolid intermediate 3-fluoro-4-(4-morpholinyl)aniline is preferably obtained by taking acompound 3, 4-difluorobenzoic acid or 3, 4-difluorobenzonitrile as a raw material, performing morpholine substitution, converting into corresponding amide and performing Hofmann degradation. Comparedwith the prior art, the method has the advantages that the raw material and reagents used in the invention are cheap and easily available, most synthesis steps can be carried out under mild conditions, the environmental pollution is small, intermediate products and end products are easy to purify, the total yield is high, the nitration reaction is effectively avoided, the requirement on equipmentis not high, and the method is more suitable for industrial production.

2, 6, 8 - Polysubstituted imidazo [1, 2 - a] pyrazine and synthesis method and application thereof

The invention discloses I, 2 and 6 polysubstituted imidazo [8 - 1] pyrazine of formula (2 - a) or a pharmaceutically acceptable salt thereof. The invention also discloses application of the 2, 6 and 8 - polysubstituted imidazo [1, 2 - a] pyrazine or pharmaceutically acceptable salts thereof as TYK2 inhibitors in preparation of drugs for preventing and treating tumor or inflammation diseases. The invention also provides a synthetic method of the 2, 6, 8 - polysubstituted imidazo [1, 2 - a] pyrazine or a pharmaceutically acceptable salt thereof.

Cyclic (Alkyl)(amino)carbene Ligand-Promoted Nitro Deoxygenative Hydroboration with Chromium Catalysis: Scope, Mechanism, and Applications

Transition metal catalysis that utilizes N-heterocyclic carbenes as noninnocent ligands in promoting transformations has not been well studied. We report here a cyclic (alkyl)(amino)carbene (CAAC) ligand-promoted nitro deoxygenative hydroboration with cost-effective chromium catalysis. Using 1 mol % of CAAC-Cr precatalyst, the addition of HBpin to nitro scaffolds leads to deoxygenation, allowing for the retention of various reducible functionalities and the compatibility of sensitive groups toward hydroboration, thereby providing a mild, chemoselective, and facile strategy to form anilines, as well as heteroaryl and aliphatic amine derivatives, with broad scope and particularly high turnover numbers (up to 1.8 × 106). Mechanistic studies, based on theoretical calculations, indicate that the CAAC ligand plays an important role in promoting polarity reversal of hydride of HBpin; it serves as an H-shuttle to facilitate deoxygenative hydroboration. The preparation of several commercially available pharmaceuticals by means of this strategy highlights its potential application in medicinal chemistry.

Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer

NUAK, the member of AMPK (AMP-activated protein kinase) family of protein kinases, is phosphorylated and activated by the LKB1 (liver kinase B1) tumor suppressor protein kinase. Recent work has indicated that NUAK1 is a key component of the antioxidant stress response pathway, and the inhibition of NUAK1 will suppress the growth and survival of colorectal tumors. As a promising target for anticancer drugs, few inhibitors of NUAK were developed. With this goal in mind, based on NUAK inhibitor WZ4003, a series of derivatives has been synthesized and evaluated for anticancer activity. Compound 9q, a derivative of WZ4003 by removing a methoxy group, was found to be the most potential one with stronger inhibitory against NUAK1/2 enzyme activity, tumor cell proliferation and inducing apoptosis of tumor cells. By in vivo efficacy evaluations of colorectal SW480 xenografts, 9q suppresses tumor growth more effectively with an excellent safety profile in vivo and is therefore seen as a suitable candidate for further investigation.

Hydroboration reduction reaction of aromatic nitro compounds without transition metal catalysis

The invention relates to a hydroboration reduction reaction of aromatic nitro compounds without transition metal catalysis. According to the method, triethyl boron and potassium tert-butoxide are used as catalysts for the first time, and an aromatic nitro compound and pinacol borane which is low in price and easy to obtain can be conveniently catalyzed to be subjected to a hydroboration reduction reaction under mild conditions to prepare aromatic amine products. Compared with a traditional method, the method generally has the advantages that the catalyst is cheap and easy to obtain, operation is convenient, and reaction is safe. The selective hydroboration reduction reaction of the non-transition metal reagent catalyzed aromatic nitro compound and pinacol borane is realized for the first time, and a practical new reaction strategy is provided for laboratory preparation or industrial production of aromatic amine products.

Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC

A series of diphenylpyrimidine derivatives bearing a hydroxamic acid group was designed and synthesized as noncovalent EGFRT790M/L858R inhibitors to improve the biological activity and selectivity. One of the most promising compound 9d effectively interfered EGFRT790M/L858R binding with ATP and suppressed the proliferation of H1975 cells with IC50 values of 1.097 nM and 0.09777 μM, respectively. Moreover, compound 9d also not only exhibited a high selective index of 43.4 for EGFRT790M/L858R over the wild-type and 10.9 for H1975 cells over A431, but also exhibited low toxicity against the normal HBE cells (IC50 > 20 μΜ). In addition, the action mechanism validated that compound 9d effectively inhibited cell migration and promoted cell apoptosis by blocking cell cycle at G2/M stage. Furthermore, the target dose-dependently downregulated the expression of p-EGFR and arrested the activation of downstream Akt and ERK in H1975. All these studies provide important clues for the discovery of potent noncovalent EGFRT790M/L858R inhibitors.

Selective Carbon-Carbon Bond Amination with Redox-Active Aminating Reagents: A Direct Approach to Anilines?

Amines are among the most fundamental motifs in chemical synthesis, and the introduction of amine building blocks via selective C—C bond cleavage allows the construction of nitrogen compounds from simple hydrocarbons through direct skeleton modification. Herein, we report a novel method for the preparation of anilines from alkylarenes via Schmidt-type rearrangement using redox-active amination reagents, which are easily prepared from hydroxylamine. Primary amines and secondary amines were prepared from corresponding alkylarenes or benzyl alcohols under mild conditions. Good compatibility and valuable applications of the transformation were also displayed.

Preparation method and application of novel 6-amino-1H-pyrazolo[3,4-d]pyrimidine JAK kinase inhibitors

The present invention provides drugs used for preventing, treating and/or ameliorating autoimmune diseases (such as psoriasis, rheumatoid arthritis, inflammatory enteritis diseases, Sjogren's syndrome, Behcet's disease, multiple sclerosis and systemic lupus erythematosus). The drugs have excellent JAK kinase inhibitory activity. The present invention also provides pharmaceutically acceptable compositions including the above compounds, and methods for preparing the compounds.

WEE1 inhibitors as well as preparation and application thereof

The invention relates to WEE1 inhibitors as well as preparation and application thereof. The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates, polymorphs or isomers thereof, and their use in the preparation of medicaments for the treatment of diseases associated with WEE1 activity.